Foghorn Therapeutics reports 2025 net loss $74.3M, cash runway into H1 2028; pipeline advances

Foghorn Therapeutics Inc.

Net loss improved to $74.3M in 2025 from $86.6M in 2024; collaboration revenue rose to $30.9M.
Cash, equivalents, and marketable securities $158.9M at Dec 31, 2025; extended runway into H1 2028 after $50M Jan 2026 financing.
Ryan Maynard appointed CFO in Feb 2026, bringing over 25 years of biopharma finance experience.
Lead candidate FHD-909 Phase 1 dose-escalation on track; collaboration with Lilly advancing.
Selective CBP and EP300 degrader programs on track for IND-enabling studies in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.